Piperlongumine
Piperlongumine (piplartine), alkaloid amide from Piper longum
Written by Aaron CuhaReviewed Sep 2026
Also known as: Piplartine, PL
A long pepper alkaloid identified in a 2016 screen as a senolytic in cultured human fibroblasts. Everything published about its senolytic activity is in cells or rats. No human study of piperlongumine for any indication was located.
Overview
Piperlongumine is a natural alkaloid amide from the long pepper, Piper longum. It came out of the same cell-based screening programme at the University of Florida that identified ABT-263 as a senolytic: piperlongumine preferentially killed senescent human WI-38 fibroblasts whether senescence had been induced by radiation, by replicative exhaustion or by oncogenic Ras, and it did so by inducing apoptosis without requiring a rise in reactive oxygen species.
The follow-up chemistry work established what part of the molecule matters. Modifications to the trimethoxyphenyl ring were tolerated, while the Michael acceptor on the lactam ring was critical for senolytic activity, and some analogues were more potent or more selective than the parent compound. In 2026 a rat study reported that piperlongumine reduced senescence and senescence-associated secretory markers in meniscus cells and chondrocytes and slowed knee osteoarthritis progression, with supporting experiments in cells taken from patients undergoing surgery.
There is no human evidence. A search of the published record located no clinical trial, no pharmacokinetic study and no registered trial of piperlongumine in people, for senescence or for anything else. No senolytic has improved a clinical outcome in a randomised trial in humans, and piperlongumine has not reached a human trial at all.
Mechanism of action
Established in cultured human cells: piperlongumine selectively induces apoptosis in senescent fibroblasts, and the alpha,beta-unsaturated lactam acts as a Michael acceptor that is required for the senolytic effect. It synergises with ABT-263 in cell culture. In rats, it reduced senescence markers in joint tissue. No mechanism has been characterised in a person, because it has not been given to one.
Human evidence
None located. No clinical trial, no pharmacokinetic study and no registered trial of piperlongumine in humans was found for any indication. Experiments on cells taken from patients are laboratory work, not human evidence about the drug.
What this does not tell you: Without any human dosing data, nothing is known about absorption, achievable plasma concentrations, or whether the concentrations that kill senescent cells in a dish are reachable in a person. The Michael acceptor chemistry that makes it senolytic is also reactive chemistry, and its human safety has not been characterised.
Reading the research record
Piperlongumine is a plant alkaloid, which means no one can own it, which means no sponsor has a commercial reason to pay for the trials that would settle what it does in people. That is an economic fact about the compound rather than a scientific verdict on it. The reverse holds with equal force: without trials, neither harm nor uselessness would be detected, and the reactive lactam chemistry that drives the senolytic effect is the kind of chemistry that usually warrants human safety data before use.
Its senolytic literature is small, recent, and dominated by the group that discovered it. The osteoarthritis result is a single rat study published in 2026 and has not been replicated.
The evidence, charted
Fig. 1 · evidence composition
0of 5 citations (0%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 2016 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- In vitro2016
Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
Cultured human WI-38 fibroblasts. Piperlongumine preferentially killed senescent cells after radiation, replicative exhaustion or oncogenic Ras expression, by apoptosis, without requiring induction of reactive oxygen species, and synergised with ABT-263. This is the originating senolytic finding and it is in cell culture.
Aging (Albany NY) - In vitro2018
Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation
Structure-activity work in cells. Modifications to the trimethoxyphenyl ring were tolerated; the Michael acceptor on the lactam ring was essential for senolytic activity. Some analogues had improved potency or selectivity.
Bioorganic and Medicinal Chemistry - Animal2026
Piperlongumine attenuates knee osteoarthritis progression by eliminating senescent meniscus cells and chondrocytes
Rat osteoarthritis model, with supporting experiments in meniscus cells and chondrocytes from patients with osteoarthritis. Piperlongumine reduced p16 and p21 and senescence-associated secretory factors and slowed disease progression in the rats. The human component is cells in a dish, not treated patients.
Biochemical and Biophysical Research Communications - In vitro2024
Piperlongumine regulates genes involved in the skin barrier in epidermal keratinocyte HaCaT cells
Human keratinocyte cell line. Gene expression work on skin barrier genes, unrelated to senescence, included here because it is representative of the compound's literature: cells, not people.
Animal Cells and Systems - Review2019
Emerging senolytic agents derived from natural products
Review placing piperlongumine among the plant-derived senolytics alongside quercetin and fisetin. A review of preclinical work; it does not report human trial data, because there is none for piperlongumine.
Mechanisms of Ageing and Development
Frequently asked questions
Has piperlongumine been tested in people?
No published human study of piperlongumine was located, for senescence or for any other use, and no trial is registered. Experiments using cells taken from patients are laboratory experiments, not trials.
Is long pepper extract the same thing?
No. Long pepper extracts sold as supplements contain piperlongumine among many other constituents at uncharacterised amounts. The published senolytic work used the isolated compound at defined concentrations in cell culture.
What has piperlongumine actually been shown to do?
In cultured human fibroblasts it selectively killed senescent cells by apoptosis and synergised with ABT-263. In rats it reduced joint senescence markers and slowed osteoarthritis progression. That is the complete evidence base.